Viking Therapeutics Shares Drop 40% Amidst Weight-Loss Trial Failures
TL;DR Summary
Viking Therapeutics experienced its worst stock decline on record, leading short sellers to profit $521 million, after a mid-stage study of its obesity pill showed significant side effects, undermining investor confidence despite analyst optimism and high price targets.
- Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40% Bloomberg
- Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate Yahoo Finance
- Viking Therapeutics shares fall 40% on disappointing obesity pill trial data CNBC
- High drop-out rate clouds weight loss data for Viking's oral drug FirstWord Pharma
- This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk. Barron's
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
86%
278 → 38 words
Want the full story? Read the original article
Read on Bloomberg